Search
Search Results
-
Neuroblastoma Discoveries and Challenges
This book provides a state-of-the-art review of the biology, treatment, and other critical aspects of neuroblastoma, reflecting the dramatic advances...
-
Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
BackgroundShort-term infusions of dinutuximab beta plus isotretinoin and cytokines administered in previous immunotherapy studies in neuroblastoma...
-
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial
BackgroundMYC genes regulate ornithine decarboxylase (Odc) to increase intratumoral polyamines. We conducted a Phase I trial [NCT02030964] to...
-
Neuroblastoma
Neuroblastoma is one of the most common childhood cancers worldwide causing approximately 10% of all pediatric cancer deaths [1–5]. More than 98% of...
-
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-clinically to the third-generation ALK inhibitor...
-
Genomic ALK alterations in primary and relapsed neuroblastoma
BackgroundGenomic alterations of the anaplastic lymphoma kinase gene ( ALK ) occur recurrently in neuroblastoma, a pediatric malignancy of the...
-
Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series
The prognosis of relapsed/refractory (R/R) neuroblastoma (NB) is dismal, calling for new therapeutic strategies. Venetoclax (VEN) is a highly...
-
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma
Activating point mutations in Anaplastic Lymphoma Kinase (ALK ) have positioned ALK as the only mutated oncogene tractable for targeted therapy in...
-
Neuroblastoma Tumor Microenvironment: Innate and Adaptive Immunity
The past twenty years have seen a resurgence of interest in cancer immunology and inclusion of immunotherapy as a treatment modality. Technological...
-
Neuroblastoma
Neurobastoma is a small round blue cell tumor that uniquely has the ability to mature and regress, either spontaneously or in response to treatment,...
-
Re-Engaging the Immune System: Immunotherapy for Neuroblastoma
Recent strategies, including immunotherapy and molecular-targeted therapy, have been extensively investigated and added clinical benefits to...
-
Role of surgery in neuroblastoma
Neuroblastoma is the most common malignant solid tumor handled by pediatric surgeons. It is well-known that neuroblastoma shows variable biological...
-
Future Aspects of Neuroblastoma Research
Discoveries in the past two decades have been pivotal in unraveling the molecular foundations of neuroblastoma, leading to a refined comprehension of...
-
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
Vα24-invariant natural killer T cells (NKTs) have anti-tumor properties that can be enhanced by chimeric antigen receptors (CARs). Here we report...
-
Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma
BackgroundNeuroblastoma is a paediatric cancer that is characterised by poor prognosis for chemoresistant disease, highlighting the need for better...
-
Immunotherapy of Neuroblastoma Targeting GD2 and Beyond
Neuroblastoma is the most common extracranial solid tumor in children. Although low-risk neuroblastoma is mostly curable, the outcome of high-risk...
-
Neuroblastoma Tumor Microenvironment: Non-Immune Cells and Exosomes
Schwann cells (SC), endothelial cells (EC), pericytes, and cancer-associated fibroblasts (CAF) are non-immune cells present in the tumor...
-
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial
BackgroundChildren with relapsed central nervous system (CNS tumors), neuroblastoma, sarcomas, and other rare solid tumors face poor outcomes. This...
-
The Genetic Basis of the Divergent Clinical Courses in Neuroblastoma
Comprehensive profiling of genomic alterations and integration of this data with other molecular and clinical information in recent years has...
-
